Remetinostat

N/A

Report date: 2025/12/31 20:01:55
NME

Base Information

Drug NameRemetinostat
Drug Alias Nameremetinostatum瑞美诺司他Methylparaben suberohydroxamic acid phenyl ester (SHAPE)37NT056AT4SHP-141C +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase inhibitors
TargetsHistone deacetylase
Therapy Area/IndicationsPlaque psoriasisAlopecia AreataCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTetralogic Pharmaceutical
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiossil IncMedivir ABTetralogic Pharmaceuticals Corp
Active IndicationsN/A
Inactive IndicationsPlaque psoriasisAlopecia AreataCarcinoma, Non-Small-Cell Lung +[5] 

Other Information

ATC CodeN/A
Related LinksWikipedia